Reaction
Small Cell Carcinoma reporting signals
As of the last recalculation, Small Cell Carcinoma appears in 339 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is ERLOTINIB (PRR 45.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Erlotinib | 7 | 45.3 | 45.3 |
| Gefitinib | 6 | 41.5 | 41.6 |
| Erlotinib Hydrochloride | 7 | 35.0 | 35.1 |
| Dabrafenib | 11 | 33.1 | 33.1 |
| Trametinib | 11 | 28.9 | 28.9 |
| Osimertinib | 8 | 15.7 | 15.7 |